Rgenix To Present Abstract on RGX-019 at the 2019 AACR Annual Meeting

New York, NY – April 1, 2019- Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today that Isabel Kurth, Ph.D., Vice President of Research at Rgenix, will present an abstract about Rgenix’s RGX-019 program at the 2019 American Association for Cancer Research Annual Meeting. The meeting is scheduled to take place Friday, March 29 through Wednesday, April 3 in Atlanta.

The details of Rgenix’s presentation are as follows:

Event: AACR Annual Meeting 2019

Date: April 3, 2019

Time: 8:00 A.M. – 12:00 P.M. EST

Description: Abstract LB-277/23, “Characterization of the anti-cancer and immunologic activity of RGX-019, a novel pre-clinical stage humanized monoclonal antibody targeting the MERTK receptor”

Location: Section 40, Georgia World Congress Center, 285 Andrew Young International Blvd NW, Atlanta, GA 30313

Kurth will present data from pre-clinical research of RGX-019, a novel
pre-clinical stage humanized monoclonal antibody targeting the MERTK receptor.

About Rgenix

Rgenix, Inc., is a privately-held
clinical-stage biopharmaceutical company focused on the discovery and
development of novel cancer drugs that target key pathways in cancer
progression. The company is pursuing several first-in-class drug candidates to
treat cancers of high unmet need. Rgenix identifies novel cancer targets using
a microRNA based target discovery platform originally developed by Rgenix’s
scientific co-founders at The Rockefeller University and now exclusively
licensed to Rgenix. The company brings together distinguished scientific
founders, a seasoned Board, and a leadership team comprised of experienced drug
developers. The company is funded by leading biotechnology investors, including
Novo Holdings A/S, Sofinnova Partners, Lepu Holdings Limited, Oceanpine
Capital, WuXi PharmaTech Healthcare Fund I, LP, Alexandria Venture
Investments,LLC, and the Partnership Fund for New York City. For more
information, please visit www.rgenix.com.

About RGX-019

RGX-019 is an investigational drug
candidate and a humanized monoclonal antibody that targets MERTK being
developed by Rgenix for the treatment of advanced cancer. Rgenix in-licensed
RGX-019 related antibody intellectual property from Rockefeller University as
part of a world-wide exclusive licensing agreement.

MERTK is a receptor tyrosine kinase of the TAM family and
is over-expressed in several human cancers. The MERTK pathway drives cancer
progression, tumor angiogenesis, and innate immune suppression. Targeting MERTK
inhibits the growth of MERTK-expressing cancer cells and induces an M1
pro-inflammatory cytokine expression profile in tumor-associated macrophages. Rgenix has initiated IND-enabling
studies of RGX-019.

Media Contacts:


Marion Janic